Dr Shezad Malik Law Firm has offices based in Fort Worth and Dallas and represents people who have suffered catastrophic and serious personal injuries including wrongful death, caused by the negligence or recklessness of others. We specialize in Personal Injury trial litigation and focus our energy and efforts on those we represent.

Articles Posted in Product Liability

ABC World News (6/28, story 7, 2:20, Sawyer) reported, “Two major studies have found the medicine called Avandia [rosiglitazone] could create a significant new risk of heart attack and other serious problems.”

The Washington Post (6/29, Stein) reports that one study, “involving more than 35,500 people, found that Avandia significantly raises the chances of a heart attack.” A separate study “of more than 227,500 Medicare patients — the largest such study to date — found that the drug boosts the risk for strokes, heart failure, and death.”

Los Angeles Times (6/29, Roan) reports that the first study “found Avandia raised the risk of heart attacks by 28% to 39% as compared with other diabetes medications. The study was published online in the Archives of Internal Medicine.”

Bloomberg News (6/29, Cortez) quotes Steven Nissen, MD, lead author of the study, as saying, “I think we’ve got more than enough evidence to say this drug should not be used.”

USA Today (6/29, Marcus) reports that in the second study, published in the Journal of the American Medical Association, “scientists from the Center for Drug Evaluation and Research at the Food and Drug Administration evaluated data from 227,571 Medicare beneficiaries taking either Avandia or Actos [pioglitazone hydrochloride].” The investigators found “no differences in the risk for heart attack between the two drugs, but the study found that compared with Actos, Avandia was associated with a 25% increased risk of heart failure, a 27% increased risk of stroke and a 14% increased risk of death.”

Lawmakers call for Avandia to be pulled from market. The Hill (6/28, Pecquet) “Healthwatch” blog reported that “Sen. Chuck Grassley (R-Iowa) and Rep. Rosa DeLauro (D-Conn.) on Monday called for the diabetes drug Avandia to be pulled from the market in the wake of two new medical studies.” In a joint statement, Sen. Grassley said, “The serious issues delineated in these two new, independent reports put additional onus on advisory committee members when they meet in July.”

Bloomberg News (6/29, Peterson, Cortez) reports that “Grassley and Senator Max Baucus, a Montana Democrat, in February released a report that said Glaxo knew Avandia may cause heart damage several years before” a “study documented the risk.”

Continue reading

The diabetes drug Avandia, once the world’s top-selling diabetes medication, took two more hits with one new study linking it to an increased risk of heart attacks and a separate study linking it to an increased risk of heart failure and stroke.

The research comes only weeks before an upcoming federal hearing to reconsider its fate. Shari Roan, LA Times 06/29/2010
The drug, known by its generic name, rosiglitazone, was approved in 1999 to help people with Type 2 diabetes control their blood sugar. At the time, it was considered a safer alternative than existing diabetes drugs used instead of insulin. Soon after approval, the drug was linked to an increased risk of heart failure and bone fractures; worries about the drug’s safety increased in 2007 when a meta-analysis — a pooling of previous studies — concluded that the drug increased the risk of heart attack.

Read Article: LA Times

Continue reading

Bloomberg News (6/18, Feeley) reported, “Pfizer Inc. faces a Texas trial over its hormone-replacement drugs after a court overseeing lawsuits over the medicines sent 200 cases back to their home courts.”

At issue in the suit is whether “the Prempro [conjugated estrogens and medroxyprogesterone] menopause drug helped cause” the plaintiff’s breast cancer.

Over “8,000 lawsuits over the medicine consolidated in federal court in Arkansas” will be “returned for trial.” Still, “Pfizer…has won dismissals of more than 3,000 cases at either the pretrial stage or after the cases have been set for trials.”

Read full story here.

Continue reading

A Florida couple who fled their dream home because of foul-smelling, ruinous Chinese drywall was awarded $2.4 million in damages in the nation’s first jury trial over the defective wallboard that could have legal ramifications for thousands of similar cases.

The defendant, drywall distributor Banner Supply, is named in thousands of other lawsuits. Associated Press, The Washington Post 06/21/2010
Read Article: The Washington Post

Continue reading

Merck & Co. lost the second trial to reach a verdict over claims its osteoporosis drug Fosamax causes so-called jaw death. The jury set damages at $8 million.

A jury in New York ruled against Merck today in the case of Shirley Boles, 72, of Fort Walton Beach, Florida. Boles claimed she developed osteonecrosis of the jaw, or ONJ, from taking Fosamax. The first Fosamax case resulted in a Merck victory in May.

Recently a link has been found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw (ONJ aka. Dead Jaw). This important discovery clearly shows that Fosamax side effects may include osteonecrosis of the jaw, aka, dead jaw or jaw death as well as osteomyelitis of the jaw. Fosamax has also been linked to low energy femur fractures (thigh bone fractures).

The case is Boles v. Merck & Co., 06-cv-09455, and the lawsuits are combined in In Re Fosamax Products Liability Litigation, MDL 1789, U.S. District Court, Southern District of New York (Manhattan).

Read full Bloomberg story here.

Continue reading

Camden County, Penn., has agreed to a $15 million settlement with a man who lost his leg and part of his arm when his car crashed into a guardrail and the railing snapped off, cutting through the vehicle.

In 2004, Nicholas Anderson was driving on Raritan Road when he was forced off the road by an oncoming car.

The lawsuit claims that the guardrail was improperly designed and should have absorbed the impact of Anderson’s vehicle instead of snapping off.

Properly designed guardrails were later installed throughout the county. Barbara Boyer , Philadelphia Inquirer 06/18/2010
Read Article: Philadelphia Inquirer

Continue reading

The Legal Intelligencer (6/23, Elliott-Engel) reports, “Drugmaker GlaxoSmithKline has agreed to settle almost 200 cases in which plaintiffs allege the use of the antidepressant Paxil caused birth defects.”

GSK “decided to settle Kilker v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline along with another 190 cases, according to an order signed by Philadelphia Common Pleas Judge Sandra Mazer Moss last week.” Jamie Sheller, “local plaintiffs liaison counsel for the Paxil pregnancy mass tort program,” estimated “that up to another 100 cases, including cases that have not yet been filed, have settled.”

Read the full story here.

Continue reading

The AP (6/4) reported, “A former physician-owner and two former employees at a Las Vegas-area colonoscopy clinic were indicted on 28 felony charges, including racketeering, negligence and insurance fraud stemming from a 2008 hepatitis C outbreak.

A judge in Las Vegas issued arrest warrants for physician Dipak Desai and former Endoscopy Center of Southern Nevada anesthetists Ronald Ernest Lakeman and Keith Mathahs on charges resulting from allegations they misused syringes and clinic instruments to transmit the incurable liver disease to seven patients.”

Read the full story here.

Continue reading

The National Law Journal (6/11, Bronstad) reports, “Dozens of sudden-acceleration lawsuits filed against Toyota Motor Corp. in California’s state courts will be coordinated in Los Angeles.

California Chief Justice Ronald George issued an order to that effect on Tuesday, following a hearing on May 21 when Los Angeles County, Calif., Superior Court Judge Carl West coordinated at least 21 lawsuits into a single proceeding.”

Read the full story here.

Continue reading

The Wall Street Journal (6/11, B4, Whalen, Mundy) reports that David Graham, an FDA drug-safety official argues in a new study that the diabetes drug Avandia (rosiglitazone) may have led to thousands of heart problems that could have been prevented if patients had been using a different medication.

The agency is already scheduled next month to evaluate the Avandia’s safety. Graham, along with other experts, has said that drug should be removed from the market.

Read the full story here.

Continue reading

Contact Information